BRPI0607551A2 - vacinas de combinação de helicobacter e circovìrus porcino e métodos de uso - Google Patents
vacinas de combinação de helicobacter e circovìrus porcino e métodos de usoInfo
- Publication number
- BRPI0607551A2 BRPI0607551A2 BRPI0607551-7A BRPI0607551A BRPI0607551A2 BR PI0607551 A2 BRPI0607551 A2 BR PI0607551A2 BR PI0607551 A BRPI0607551 A BR PI0607551A BR PI0607551 A2 BRPI0607551 A2 BR PI0607551A2
- Authority
- BR
- Brazil
- Prior art keywords
- vaccines
- helicobacter
- methods
- pigs
- circovirus
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 6
- 241000589989 Helicobacter Species 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 241001533384 Circovirus Species 0.000 title abstract 2
- 241000282887 Suidae Species 0.000 abstract 3
- 208000025865 Ulcer Diseases 0.000 abstract 2
- 238000002649 immunization Methods 0.000 abstract 2
- 230000003053 immunization Effects 0.000 abstract 2
- 241000894007 species Species 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 230000036269 ulceration Effects 0.000 abstract 2
- 238000002255 vaccination Methods 0.000 abstract 2
- 241001202111 Cerambyx cerdo Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 241000202347 Porcine circovirus Species 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10041—Use of virus, viral particle or viral elements as a vector
- C12N2750/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
VACINAS DE COMBINAçãO DE HELICOBACTER E CIRCOVìRUS PORCINO E MéTODOS DE USO. A presente invenção refere-se a descoberta de novas espécies do gênero Helicobacter que estão associadas com ulceração gastroesofágica em porcos. Em particular, uma nova espécie, H. cerdo, foi usada como uma fonte de material antigênico para o desenvolvimento de vacina para o tratamento dos distúrbios gastroesofágicos. Mais vantajosamente, os novos Helicobacter e os circovírus porcinos associados com a síndrome debilitante multissitêmica pós-desmame em porcos são úteis para proporcionar vacinas de combinação por meio das quais imunogênios derivados de ambos os tipos de patógenos podem ser coliberados para o animal-alvo para estimular a produção de anticorpos protetores e imunidade. A invenção, portanto, proporciona vacinas que são úteis para o tratamento de ulceração gastroesofágica e síndrome debilitante multissitêmica pós-desmame em porcinos. A invenção inclui, portanto, composições e vacinas imunogênicas multivalentes, kits multivacinas, e métodos combinados de imunização ou vacinação os quais tornam possível usar os programas combinados de imunização ou vacinação referidos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/107,219 US20060029617A1 (en) | 1997-10-03 | 2005-04-15 | Porcine circovirus and Helicobacter combination vaccines and methods of use |
PCT/US2006/013935 WO2006113372A2 (en) | 2005-04-15 | 2006-04-13 | Porcine circovirus and helicobacter combination vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0607551A2 true BRPI0607551A2 (pt) | 2009-09-15 |
Family
ID=37027631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0607551-7A BRPI0607551A2 (pt) | 2005-04-15 | 2006-04-13 | vacinas de combinação de helicobacter e circovìrus porcino e métodos de uso |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060029617A1 (pt) |
EP (1) | EP1871884A2 (pt) |
CN (1) | CN101198699A (pt) |
AR (1) | AR053711A1 (pt) |
BR (1) | BRPI0607551A2 (pt) |
CA (1) | CA2604705A1 (pt) |
CL (1) | CL2006000880A1 (pt) |
TW (1) | TW200719912A (pt) |
WO (1) | WO2006113372A2 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100879650B1 (ko) * | 1997-12-11 | 2009-01-20 | 유니버시티 오브 사스카췌완 | 돼지로부터의 이유후 다기관계작용성 소모 증후군 바이러스 |
US8029777B2 (en) * | 2004-08-13 | 2011-10-04 | Marshall Barry J | Helicobacter system and uses thereof |
JP2008509168A (ja) | 2004-08-13 | 2008-03-27 | マーシャル,バリー,ジェー. | 細菌デリバリシステム |
US7833707B2 (en) | 2004-12-30 | 2010-11-16 | Boehringer Ingelheim Vetmedica, Inc. | Methods of overexpression and recovery of porcine circovirus type 2 ORF2 |
UA95602C2 (ru) | 2004-12-30 | 2011-08-25 | Берингер Ингельхейм Ветмедика, Инк. | Иммуногенная композиция цвс2 и способы приготовления такой композиции |
US7700285B1 (en) | 2005-12-29 | 2010-04-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
EP3868400A1 (en) | 2005-12-29 | 2021-08-25 | Boehringer Ingelheim Animal Health USA Inc. | Multivalent pcv2 immunogenic compositions and methods of producing such compositions |
PT2371383E (pt) * | 2005-12-29 | 2015-11-24 | Boehringer Ingelheim Vetmed | Utilização de uma composição imunogénica de pcv2 para atenuar os sintomas clínicos em porcos |
WO2008064299A2 (en) * | 2006-11-22 | 2008-05-29 | Boehringer Ingelheim Vetmedica, Inc. | Methods of reducing porcine circovirus-associated disease outbreaks |
EP2101815A4 (en) * | 2006-12-11 | 2010-10-06 | Boehringer Ingelheim Vetmed | EFFICIENT PROCESS FOR THE TREATMENT OF PORCINE CIRCOVIRUS AND LAWSONIA INTRACELLULARIS INFECTIONS |
US8865183B2 (en) * | 2006-12-15 | 2014-10-21 | Boehringer Ingelheim Vetmedica, Inc. | Treatment of pigs with PCV2 antigent |
EP1941903A1 (en) | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxis and treatment of PRDC |
EP1958644A1 (en) | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Prevention and treatment of sub-clinical pcvd |
US7829274B2 (en) * | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
BRPI0821456A2 (pt) * | 2007-12-31 | 2015-06-16 | Boehring Ingelheim Vetmedica Inc | Partícula similar à pcv2 orf2 com inserção de aminoácido estranho |
EP2242511A4 (en) | 2008-01-23 | 2012-10-24 | Boehringer Ingelheim Vetmed | IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS |
US20110033495A1 (en) * | 2008-02-15 | 2011-02-10 | Boehringer Ingelheim Vetmedica, Inc. | Methods and compositions for reducing the impact of enteric diseases |
AR078253A1 (es) | 2009-09-02 | 2011-10-26 | Boehringer Ingelheim Vetmed | Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad |
CN102973932A (zh) * | 2011-09-07 | 2013-03-20 | 普莱柯生物工程股份有限公司 | 猪繁殖与呼吸综合征、猪圆环病毒病与猪伪狂犬病三联灭活疫苗以及其制备方法 |
CN102406936A (zh) * | 2011-11-22 | 2012-04-11 | 青岛易邦生物工程有限公司 | 一种鸡传染性鼻炎灭活疫苗佐剂 |
CN103893749A (zh) * | 2012-12-29 | 2014-07-02 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法和应用 |
CN103920146A (zh) * | 2013-01-14 | 2014-07-16 | 普莱柯生物工程股份有限公司 | 猪圆环病毒ⅱ型与猪伪狂犬病二联疫苗及其制备方法和应用 |
KR20220083861A (ko) | 2013-10-02 | 2022-06-20 | 베링거 인겔하임 애니멀 헬스 유에스에이 인크. | Pcv2 orf2 단백질 변이체 및 이로 이루어진 바이러스 유사 입자 |
RO132299A3 (ro) | 2017-06-06 | 2018-12-28 | Fântână Raul Sorin | Compoziţie şi metodă de preparare şi evaluare a unui imunogen complex numit i-spga, destinat producerii de proteine imunologic active () |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA78180C2 (uk) * | 1997-10-03 | 2007-03-15 | Меріаль | Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти |
GB9921147D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
RU2005127573A (ru) * | 2003-02-03 | 2006-01-27 | Сирибас Байолоджикалз, Инк. (Us) | Способы лечения, профилактики инфекции helicobacter |
-
2005
- 2005-04-15 US US11/107,219 patent/US20060029617A1/en not_active Abandoned
-
2006
- 2006-04-13 CA CA002604705A patent/CA2604705A1/en not_active Abandoned
- 2006-04-13 WO PCT/US2006/013935 patent/WO2006113372A2/en active Application Filing
- 2006-04-13 BR BRPI0607551-7A patent/BRPI0607551A2/pt not_active Application Discontinuation
- 2006-04-13 CN CNA2006800211701A patent/CN101198699A/zh active Pending
- 2006-04-13 EP EP06740938A patent/EP1871884A2/en not_active Withdrawn
- 2006-04-17 TW TW095113707A patent/TW200719912A/zh unknown
- 2006-04-17 AR ARP060101493A patent/AR053711A1/es unknown
- 2006-04-17 CL CL2006000880A patent/CL2006000880A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2604705A1 (en) | 2006-10-26 |
WO2006113372A3 (en) | 2007-06-14 |
TW200719912A (en) | 2007-06-01 |
CL2006000880A1 (es) | 2009-08-07 |
WO2006113372A2 (en) | 2006-10-26 |
AR053711A1 (es) | 2007-05-16 |
EP1871884A2 (en) | 2008-01-02 |
CN101198699A (zh) | 2008-06-11 |
US20060029617A1 (en) | 2006-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0607551A2 (pt) | vacinas de combinação de helicobacter e circovìrus porcino e métodos de uso | |
ME01199B (me) | Nove kompozicije adjuvanta | |
CY1118492T1 (el) | Φαρμακοτεχνικες μορφες εμβολιου norovirus | |
DK1898948T3 (da) | Polyriboinosinsyre-polyribocytidylsyre-baseret adjuvans | |
TW200719910A (en) | C. perfringens alpha toxoid vaccine | |
BRPI0621181A8 (pt) | Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico | |
EA201491171A1 (ru) | Вещества, содержащие улучшенные генетические конструкции il-12, вакцины, иммунотерапевтические составы и способы их применения | |
MX2013010620A (es) | Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo. | |
AR090294A1 (es) | Composiciones de neisseria meningitidis y metodos de las mismas | |
EA200701786A1 (ru) | Поливалентная противогриппозная иммуногенная композиция | |
BRPI1007721B1 (pt) | composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66 | |
ME01140B (me) | Virus goveđe virusne dijareje s modifikovanim erns proteinom | |
BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
CY1112575T1 (el) | Βελτιωμενα αδρανοποιημενα εμβολια fcv | |
NZ731659A (en) | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus | |
BR112014020025A2 (pt) | vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas | |
PE20180463A1 (es) | Virus de la enteritis del pato y usos del mismo | |
SE0602550L (sv) | Nya formuleringar för behandling av TH2 medierade inflamatoriska sjukdomar | |
AR101256A1 (es) | Composición vacunal que comprende ipv y ciclodextrinas | |
WO2008121487A3 (en) | Live attenuated virus vaccines for la crosse virus and other bunyaviridae | |
BR112014026812A8 (pt) | Antígenos e combinações de antígenos | |
DK1742656T3 (da) | Hidtil ukendt jordnøddeskindekstrakt som adjuvansvaccine | |
BR112018015255A2 (pt) | extrato de streptococcus uberis como um agente imunogênico | |
BR112012033751A2 (pt) | composição de vacina, célula, adjuvante, método de vacinar um paciente contra e. canis e processos para produzir a composição de vacina e o antígeno de e. canis | |
UY29528A1 (es) | Vacunas de combinacinn para circovirus porcino y helicobacter y mctodo de uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |